Base Editing (ABE8e) for TCIRG1 c.630G>A (p.Thr210=) in Autosomal recessive osteopetrosis

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Autosomal recessive osteopetrosis targeting the TCIRG1 c.630G>A (p.Thr210=) variant (Pathogenic, 5 prime UTR variant, synonymous variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct loss-of-function TCIRG1 mutations in hematopoietic stem cells at the TCIRG1 locus to restore osteoclast acidification and cure autosomal recessive osteopetrosis. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: TCIRG1 NM_006019.4(TCIRG1):c.630G>A (p.Thr210=) is classified as Pathogenic (ClinVar variation ID 1458586). Molecular consequence: 5 prime UTR variant, synonymous variant. 2. Epidemiology: Incidence approximately 1 in 200,000-250,000 live births with higher prevalence in consanguineous populations; over 50% of ARO due to TCIRG1, 10-15% due to CLCN7, smaller fractions due to OSTM1, CA2 and others. 3. Standard of care: Early allogeneic hematopoietic stem cell transplantation is the only curative option for osteoclast-intrinsic forms; ACTIMMUNE (interferon gamma-1b) is FDA-approved to delay progression as adjunctive, non-curative therapy; additional care is supportive (transfusions, infection management, orthopedic 4. Pipeline: HSCT is established standard of care; interferon gamma-1b is approved pharmacologic therapy; lentiviral ex vivo TCIRG1 gene therapy is in preclinical development with murine rescue data; no registered CRISPR or other gene-editing clinical trials for ARO as of 2024; gene-editing work remains preclini 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting TCIRG1 c.630G>A (p.Thr210=) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.